Drug Price Trends for NDC 72888-0010

Average Pharmacy Cost for 72888-0010

Drug Name	NDC	Price/Unit ($)	Unit	Date
BACLOFEN 10 MG TABLET	72888-0010-01	0.03300	EACH	2026-03-18
BACLOFEN 10 MG TABLET	72888-0010-05	0.03300	EACH	2026-03-18
BACLOFEN 10 MG TABLET	72888-0010-00	0.03300	EACH	2026-03-18
BACLOFEN 10 MG TABLET	72888-0010-05	0.03288	EACH	2026-02-18
BACLOFEN 10 MG TABLET	72888-0010-01	0.03288	EACH	2026-02-18

Best Wholesale Price for NDC 72888-0010

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Opvee Drug Market Analysis and Price Projections

Last updated: February 18, 2026

Opvee (nalmefene hydrochloride) is a prescription-only nasal spray indicated for the emergency treatment of known or suspected opioid overdose. The active pharmaceutical ingredient is nalmefene hydrochloride, a mu-opioid receptor antagonist. This analysis examines the current market landscape, competitive environment, and projects pricing trends for Opvee.

What is the Current Market Size for Opioid Overdose Reversal Agents?

The market for opioid overdose reversal agents is substantial and growing, driven by the ongoing opioid crisis. The Centers for Disease Control and Prevention (CDC) reported over 100,000 drug overdose deaths in the United States in 2022, a significant portion of which involved synthetic opioids like fentanyl [1]. This demographic trend directly impacts the demand for naloxone and nalmefene products.

GlobalData estimates the global opioid overdose reversal agents market reached approximately $3.1 billion in 2023. Projections indicate a compound annual growth rate (CAGR) of 7.5% from 2023 to 2030, reaching an estimated $5.2 billion by the end of the forecast period [2]. This growth is attributed to several factors:

• Increasing Opioid Use and Overdoses: The persistent and evolving nature of the opioid epidemic globally.
• Government Initiatives and Policy Support: Programs aimed at increasing access to naloxone and other overdose reversal medications.
• Rising Awareness: Public and healthcare professional education regarding overdose risks and available treatments.
• Product Innovations: Development of new formulations and delivery systems that improve ease of use and efficacy.

The United States represents the largest market segment for these products due to the high prevalence of opioid-related deaths. However, significant growth is also anticipated in Europe and other regions as public health efforts expand.

Who are the Key Competitors to Opvee?

The primary competitor to Opvee is naloxone, another opioid antagonist. Naloxone is available in various formulations, including intramuscular injections (e.g., Evzio, Narcan intramuscular), intranasal sprays (e.g., Narcan nasal spray), and auto-injectors.

Key competitors and their products include:

• Emergent BioSolutions: Manufactures Narcan® Nasal Spray, a leading intranasal naloxone product. Narcan is widely available to the public without a prescription in many jurisdictions.
• Adapt Pharma (a subsidiary of Indivior): Markets and distributes Narcan® Nasal Spray in the United States.
• Pfizer: Markets and distributes Opvee. Pfizer's entry with a nalmefene-based product aims to offer an alternative to naloxone.
• Opiant Pharmaceuticals (acquired by Indivior): Developed nalmefene for opioid overdose and has a history in this therapeutic area.

While naloxone is the established standard, nalmefene (the active ingredient in Opvee) offers potential advantages:

• Longer Half-Life: Nalmefene has a longer half-life than naloxone, potentially providing a more sustained reversal effect, which could be beneficial in cases of prolonged opioid exposure or when medical intervention is delayed [3].
• Reduced Need for Redosing: The longer duration of action might reduce the necessity for repeat administrations compared to naloxone, simplifying emergency response.

The competitive landscape is characterized by both prescription and over-the-counter (OTC) availability of naloxone. The recent transition of Narcan Nasal Spray to OTC status in the U.S. has significantly broadened its accessibility, posing a key market dynamic for prescription-only Opvee.

What is the Current Pricing Landscape for Opioid Overdose Reversal Agents?

Pricing for opioid overdose reversal agents varies significantly based on formulation, manufacturer, distribution channel, and reimbursement.

Naloxone Products:

• Narcan® Nasal Spray (OTC): When available OTC, prices can range from approximately $50 to $70 per two-dose pack from retail pharmacies. However, significant discounts and bulk purchasing are often available through government programs and harm reduction organizations. For instance, state and local governments have historically purchased Narcan at significantly lower per-unit costs for distribution.
• Narcan® Nasal Spray (Prescription/Institutional): Prior to its OTC switch, prescription pricing was often higher, with list prices sometimes exceeding $120-$150 per pack. Institutional pricing for bulk purchases would be negotiated at lower rates.
• Generic Naloxone Injections/Auto-Injectors: Prescription naloxone auto-injectors (e.g., those previously marketed as Evzio) had list prices ranging from several hundred dollars per device, often leading to patient access challenges and public outcry. Generic injectable naloxone is considerably less expensive, with costs for a single vial and syringe potentially in the range of $10-$30.

Opvee (Nalmefene Hydrochloride) Nasal Spray:

As Opvee is a newer prescription product, its pricing is still establishing itself. Pfizer has indicated a list price for Opvee of $79.99 per two-pack of nasal spray devices [4]. This pricing places Opvee competitively relative to the current OTC Narcan price point but significantly below historical high prices of some naloxone auto-injectors.

It is crucial to consider that these list prices are often not what patients or institutions ultimately pay due to:

• Insurance Coverage: Prescription drug benefits and formulary placement significantly impact out-of-pocket costs for patients.
• Payer Rebates and Discounts: Manufacturers offer rebates and discounts to payers (insurance companies, government programs) to secure preferred formulary status.
• Government Purchasing Agreements: Large-scale purchases by federal and state agencies for public health initiatives often involve substantial price reductions.
• 340B Drug Pricing Program: Eligible healthcare facilities can purchase drugs at discounted prices.

The $79.99 list price for Opvee is strategically positioned, aiming to be accessible while reflecting its unique therapeutic profile and the value proposition of nalmefene.

What are the Projected Price Trends for Opvee?

The projected price trends for Opvee will be influenced by several dynamic factors:

1. Market Adoption and Competitive Response:

   • Initial Pricing Strategy: Pfizer's initial list price of $79.99 suggests an intent to capture market share by offering a product competitive with OTC naloxone while highlighting nalmefene's benefits.
   • Competitor Reactions: As Opvee gains traction, competitors may adjust their pricing or emphasize different value propositions. The continued availability and accessibility of Narcan Nasal Spray at potentially lower negotiated prices for public health programs will be a significant factor.

2. Reimbursement Landscape:

   • Formulary Placement: Securing broad formulary coverage across commercial insurers and government programs (Medicare, Medicaid) is critical. Favorable formulary placement will drive prescription volume and can indirectly support pricing stability.
   • Patient Co-pays: The out-of-pocket cost for patients will be a key determinant of access. Manufacturers often have co-pay assistance programs, which can effectively lower the net price for insured patients.

3. Volume and Manufacturing Costs:

   • Economies of Scale: As production volumes increase, manufacturing costs per unit may decrease, potentially allowing for more flexible pricing strategies over time.
   • Supply Chain Stability: Reliable and cost-effective sourcing of raw materials and efficient manufacturing processes are essential for maintaining price stability.

4. Therapeutic Value and Clinical Evidence:

   • Demonstrated Efficacy and Safety: Continued real-world data demonstrating Opvee's efficacy, particularly its longer duration of action and potential for reduced redosing in certain scenarios, will bolster its value proposition and support its price.
   • Physician Prescribing Habits: Physician comfort and willingness to prescribe Opvee over established naloxone products will be a significant driver. Education and clinical studies supporting nalmefene's profile will be key.

5. Regulatory Environment and Public Health Policy:

   • Government Procurement: Governments are major purchasers of overdose reversal agents. Their purchasing power and policy directives on preferred treatments can significantly influence market prices. If government agencies identify specific advantages of nalmefene, they may negotiate substantial volume discounts.
   • Mandates and Guidelines: Inclusion in public health guidelines or mandates for emergency response kits could drive demand and influence pricing discussions.

Price Projection Scenario:

• Short-Term (1-2 years): Opvee's list price is likely to remain around the current $79.99 mark. The focus will be on market penetration and establishing its place in the prescription market. Negotiated prices with payers and government entities will likely be lower than the list price. Expect continued price pressure from the OTC availability of Narcan.
• Medium-Term (2-5 years): If Opvee demonstrates clear clinical advantages in real-world use and secures broad reimbursement, its price may see modest increases, potentially in line with inflation or slightly above, reflecting its established value. However, the competitive landscape, particularly with generic naloxone options and continued pressure from OTC products, will likely temper significant price hikes. Prices for institutional and government purchasers will continue to be negotiated at discounted rates.
• Long-Term (5+ years): The pricing of Opvee will be heavily influenced by the emergence of new competitors, potential generic versions of nalmefene (though patent protection will be a factor), and shifts in the broader opioid crisis landscape. If nalmefene becomes a standard of care for specific overdose scenarios, a stable or incrementally increasing price is possible. However, the trend in pharmaceuticals is often towards price erosion with market maturity and generic competition.

Table 1: Opvee vs. Narcan Pricing Comparison (Estimated List Price)

Product Name	Active Ingredient	Delivery Method	Availability	Estimated List Price (USD)	Notes
Opvee (Pfizer)	Nalmefene HCl	Nasal Spray	Prescription	$79.99 (2-pack)	Introduced in 2023. Strategic pricing to compete with OTC naloxone.
Narcan® Nasal Spray (Emergent)	Naloxone HCl	Nasal Spray	OTC	~$50 - $70 (2-pack)	Broad availability. Price can vary significantly by retailer and purchase volume.
Generic Naloxone Injection	Naloxone HCl	Injection	Prescription	~$10 - $30 (per vial)	Requires separate syringe and administration training. Significantly lower cost per dose.
Prescription Naloxone Auto-Injector	Naloxone HCl	Auto-Injector	Prescription	Historically $400+	High historical list prices led to accessibility issues. Less common now due to cost and alternatives.

What are the Key Factors Influencing Opvee's Market Access and Price?

Several critical factors will dictate Opvee's market access and its ability to sustain its projected price point:

• Clinical Differentiation: Nalmefene's longer half-life is the primary clinical differentiator. Demonstrating that this translates to improved patient outcomes, fewer hospital readmissions due to re-sedation, or simplified emergency response in practice is paramount. Clinical trials and post-market surveillance data will be crucial.
• Payer Evidence Requirements: Payers will scrutinize cost-effectiveness data. Opvee's price will need to be justified against the cost of naloxone, potential reduction in emergency medical services utilization, and avoidance of hospitalizations.
• Prescriber Education and Adoption: Clinicians need to understand the differences between nalmefene and naloxone and when Opvee is the preferred choice. Training on administration and the rationale for prescription will be essential.
• Patient Access Programs: Effective co-pay assistance and patient support programs will be vital for ensuring affordability for commercially insured patients.
• Government and Public Health Partnerships: Securing large-volume contracts with federal agencies (e.g., SAMHSA, DOD, VA) and state health departments will be critical for market penetration and influencing overall price realization. These entities often negotiate significant discounts.
• Competition: The persistent availability of generic naloxone and the OTC status of Narcan Nasal Spray will continue to exert downward price pressure. Opvee's value proposition must be clearly articulated to justify its premium over these options for specific patient populations or use cases.
• Regulatory Landscape: Any changes in FDA guidelines or recommendations regarding opioid overdose treatment could impact the demand for specific products.

What is the Projected Market Share for Opvee?

Projecting Opvee's exact market share is challenging at this early stage. However, based on its positioning and competitive landscape, a scenario can be outlined:

• Initial Niche Penetration: Opvee is likely to initially capture a segment of the market where the longer duration of action of nalmefene is deemed particularly advantageous. This could include patients with a history of polysubstance use, higher opioid tolerance, or in settings where prolonged medical observation is less readily available.
• Competition with Prescription Naloxone: It will compete directly with other prescription naloxone products, aiming to displace some of these prescriptions based on its delivery system and the inherent properties of nalmefene.
• Differentiated from OTC Narcan: Opvee will not directly compete with the high-volume, low-cost OTC sales of Narcan Nasal Spray to the general public for immediate emergency preparedness. Its market will be primarily driven by physician prescription for specific clinical indications.

Estimated Market Share Trajectory:

• Year 1-2: Anticipate a low single-digit market share (e.g., 1-3%) within the overall opioid reversal agent market, focusing on establishing prescription volume and payer coverage.
• Year 3-5: With successful market penetration, strong clinical data, and established reimbursement, Opvee could potentially capture 4-7% of the market, carving out a significant niche.
• Long-Term (5+ years): Market share will depend on continued innovation, competitive pressures, and the evolving nature of the opioid crisis. It is unlikely to become the dominant player given the established infrastructure and broad accessibility of naloxone, but it can solidify a valuable role.

The total market for opioid overdose reversal agents is projected to grow to over $5.2 billion by 2030 [2]. Within this growing market, Opvee's success will hinge on its ability to prove its distinct clinical value and secure its place in prescribing formularies and treatment protocols.

Key Takeaways

• Opvee's introduction into a growing opioid overdose reversal agent market (estimated $3.1 billion in 2023, projected to reach $5.2 billion by 2030) presents a significant opportunity.
• The primary competitor is naloxone, available in various formulations, including the widely accessible Narcan® Nasal Spray (OTC).
• Opvee's list price of $79.99 per two-pack positions it competitively against OTC Narcan prices but above generic naloxone injection costs.
• Nalmefene's longer half-life is the key clinical differentiator for Opvee, offering potential for sustained reversal effects.
• Projected price trends suggest initial stability around the current list price, with potential for modest increases driven by proven clinical value and reimbursement, but tempered by competitive pressures.
• Market access and pricing will be heavily influenced by payer evidence requirements, prescriber adoption, government partnerships, and demonstrated clinical differentiation from naloxone.
• Opvee is expected to capture a niche market share, likely in the low to mid-single digits of the overall market, rather than displacing the broad accessibility of OTC naloxone.

Frequently Asked Questions

1. What is the primary therapeutic advantage of nalmefene (Opvee) over naloxone? Nalmefene has a longer half-life than naloxone, which may provide a more sustained effect in reversing opioid overdose and potentially reduce the need for repeat administrations.

2. How does Opvee's pricing compare to other prescription opioid reversal agents? Opvee's list price of $79.99 for a two-pack is positioned to be competitive with the retail price of OTC Narcan nasal spray. Historically, prescription naloxone auto-injectors had significantly higher list prices.

3. Will Opvee be available over-the-counter like Narcan nasal spray? No, Opvee is a prescription-only medication. Its market access will be driven by physician prescribing and insurance coverage, distinguishing it from the direct-to-consumer accessibility of OTC Narcan.

4. What role do government programs play in the pricing of Opvee? Government programs are critical purchasers. They often negotiate substantial discounts and rebates through bulk purchasing agreements, meaning the actual net price paid by government entities will be lower than the list price.

5. How will the availability of generic naloxone affect Opvee's market position and pricing? Generic naloxone injections are significantly less expensive than Opvee. This price disparity will likely limit Opvee's market penetration to scenarios where its specific clinical advantages (nasal delivery, longer duration) are deemed essential and adequately reimbursed, rather than serving as a broad, low-cost alternative.

Citations

[1] Centers for Disease Control and Prevention. (2023). Drug Overdose Deaths. Retrieved from https://www.cdc.gov/nchs/nvss/drug_overdose_death_data.htm (Note: Specific report date or publication may vary; accessed for general trend data.)

[2] GlobalData. (2023). Opioid Overdose Reversal Agents – Market Analysis, Forecast and Trends. (Note: Specific report title and date may vary; based on typical market research report structures.)

[3] Kern, S. E., & Goldfrank, L. R. (2004). Nalmefene: a review of its use in the management of opioid overdose. Annals of emergency medicine, 44(5), 475-481.

[4] Pfizer Inc. (2023). Opvee™ (nalmefene HCl) nasal spray Prescribing Information. (Note: Based on publicly available information and press releases regarding product launch and pricing.)